Life AI Net
Home
Archive
Calculators
Directory
Newsletter
Login
English
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
Home
Archive
Calculators
Directory
Newsletter
English
简体中文
Deutsch
Français
Español
日本語
한국어
العربية
Auto
Login
Home
Archive
Calculators
Directory
More
Live
FierceBiotech
Parabilis preps $413M IPO to fuel desmoid tumor drug into phase 3
Lonza News
Stipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila Times
Lonza News
Stipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila Times
Endpoints News
Parabilis Medicines charts $413M IPO to back peptide pipeline
FierceBiotech
Innovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADC
PharmaVoice
House bill aims to crack down on China biotech deals
PharmaVoice
Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
FierceBiotech
Medline earns FDA warning letter ire for repeated toxic bacteria problems
FierceBiotech
From business strategy to CAR-T responses, for Cabaletta it’s all about ‘durability’
BioWorld
FDA clears Shionogi’s Xocova as first COVID-19 prevention pill
Bruker
Bruker showcases expanded microbiology diagnostics portfolio - Investing.com
Bruker
Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026 - 巴士的報
FierceBiotech
Parabilis preps $413M IPO to fuel desmoid tumor drug into phase 3
Lonza News
Stipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila Times
Lonza News
Stipple Bio Enters Multi-Target License Agreement with Lonza to Advance Precision Oncology ADC Therapies - The Manila Times
Endpoints News
Parabilis Medicines charts $413M IPO to back peptide pipeline
FierceBiotech
Innovent, fresh from $1.2B deal, posts phase 3 win for Takeda-partnered ADC
PharmaVoice
House bill aims to crack down on China biotech deals
PharmaVoice
Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
FierceBiotech
Medline earns FDA warning letter ire for repeated toxic bacteria problems
FierceBiotech
From business strategy to CAR-T responses, for Cabaletta it’s all about ‘durability’
BioWorld
FDA clears Shionogi’s Xocova as first COVID-19 prevention pill
Bruker
Bruker showcases expanded microbiology diagnostics portfolio - Investing.com
Bruker
Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026 - 巴士的報
Archive
This story is not available in the archive.